Table 1.
|
Demographic character |
|
Methodological character |
|
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study |
ASD |
TD |
|
|
|
|
|
|
|
|
Value |
Multiple comparison correction |
||||||||||||||||
Na | Males | Mean age (years) | IQb | Nc | Males | Mean age (years) | IQb | Diagnostic tools | Medication / comorbidity | Tesla | B factor | Number of direction | NEX | TE/TR (ms) | Type of WBA | Software | FA | MD | RD | AD | ADC | Threshold | FWE | FDR | TFCE | Permutation | Main results | |
Whole brain voxel-wise analysis study | ||||||||||||||||||||||||||||
Ameis and colleagues [43] |
19 |
16 |
12.4 |
99 |
16 |
8 |
12.3 |
101 |
DSM-IV/ADI-R/ADOs |
No/No |
3 |
1,250 |
12 |
5 |
80/4,100 |
TBSS |
FSL4.1 |
○ |
○ |
○ |
○ |
○ |
P <0.05 |
○ |
× |
○ |
× |
MD↓ in UF, IFOF, CC, SLF, in ASD children |
Barnea-Goraly and colleagues [44] |
7 |
7 |
14.6 |
101 |
9 |
9 |
13.4 |
107 |
ADI-R/ADOS |
NA/Na |
3 |
900 |
6 |
4 |
106/6,000 |
Voxel Based Whole Brain |
SPM99 |
○ |
× |
× |
× |
× |
P <0.05 |
× |
× |
× |
× |
FA↓ in Cg, UF, in ASD |
Barnea-Goraly and colleagues [18] |
13 |
11 |
10.5 |
86 |
11 |
9 |
9.6 |
120 |
ADI-R/ADOS |
NA/No |
1.5 |
900 |
6 |
4 |
106/6,000 |
TBSS |
FSL4.1 |
○ |
× |
○ |
○ |
× |
P <0.05 |
○ |
× |
○ |
○ |
FA↓ in CC, SLF, in ASD |
Bloemen and colleagues [45] |
13 |
113 |
39 |
110 |
13 |
13 |
37 |
115 |
ICD-10/ADI-R/ADOS |
NA/No |
NA |
1,300 |
4 |
NA |
107/15,000 |
Voxel Based Whole Brain |
SPM2 |
○ |
○ |
○ |
× |
× |
P <0.05 |
NA |
NA |
× |
○ |
FA↓ in IFOF, ILF, CC, SLF, Cg, in ASD |
Bode and colleagues [46] |
27 |
20 |
14.7 |
NA |
26 |
17 |
14.5 |
NA |
ADI-R/ADOS |
NA/No |
NA |
100 |
NA |
1 |
90/8,000 |
TBSS |
FSL |
○ |
○ |
× |
× |
× |
P <0.0005 |
NA |
NA |
× |
× |
FA↓ in IFOF |
Cheung and colleagues [48] |
13 |
12 |
9.3 |
100 |
14 |
13 |
9.9 |
112 |
ICD-10/ADI-R |
No/No |
1.5 |
1,200 |
25 |
NA |
100/10,000 |
Voxel Based Whole Brain |
SPM2 |
○ |
× |
× |
× |
× |
P <0.0005 |
× |
× |
× |
× |
FA↓ in SLF, FA, in ASD |
Groen and colleagues [49] |
17 |
14 |
14.4 |
98 |
25 |
22 |
15.5 |
105 |
ADI-R |
No/No |
1.5 |
900 |
30 |
4 |
93/10,100 |
Voxel Based Whole Brain |
SPM5 |
○ |
○ |
× |
× |
× |
P <0.05 |
× |
○ |
× |
× |
FA↓ in SLF, ILF, in ASD |
Jeong and colleagues [50] |
32 |
29 |
439 |
NA |
14 |
11 |
5.61 |
NA |
DSM-IV |
NA/No |
3 |
1,000 |
6 |
6 |
NA/1,250 |
Whole Brain Tractography |
FSL |
○ |
○ |
× |
× |
× |
Various |
× |
○ |
× |
× |
FA↓ in, AF <UF, CC in ASD |
Jou and colleagues [51] |
15 |
15 |
10.9 |
NA |
8 |
8 |
11.5 |
NA |
DSM-IV/ADI-ADOS |
NA/NA |
3 |
NA |
30 |
3 |
85/6,200 |
TBSS |
FSL |
○ |
× |
○ |
○ |
× |
P <0.05 |
NA |
NA |
○ |
× |
FA↓ in IFOF, SLF, UF, Cg, in ASD |
Jou and colleagues [52] |
10 |
10 |
13.5 |
91 |
10 |
10 |
13.5 |
105 |
DSM-IV/ADI-R/ADOS |
NA/NA |
1.5 |
1,000 |
6 |
6 |
92/1,1200 |
Voxel Based Whole Brain |
Biolmage Suite |
○ |
× |
× |
× |
× |
p<0.05 |
× |
× |
× |
× |
FA↓ in CC, CG, SLF, IFOF, ILF, in ASD |
Ke and colleagues [53] |
12 |
12 |
8375 |
101 |
12 |
12 |
9.4 |
100 |
DSM-IV/ADI-R |
NA/No |
1.5 |
1,000 |
15 |
2 |
104.4/8,000 |
Voxel Based Whole Brain |
SPMS |
○ |
× |
× |
× |
× |
p<0.05 |
× |
× |
× |
× |
No peak coordinates reported in cortical fibers |
Kumar and colleagues [26] |
32 |
29 |
5 |
NA |
16 |
12 |
5.5 |
NA |
DSM-IV |
NA/No |
3 |
1,000 |
6 |
6 |
79/1,0000 |
TBSS |
FSL |
○ |
× |
× |
× |
○ |
p<0.05 |
× |
× |
× |
× |
FA↓ in rt UF, IFO, AF, rt Cg, CC in ASD |
Noriuchi and colleagues [54] |
7 |
6 |
14 |
93 |
7 |
6 |
13.4 |
116 |
DSM-IV |
NA/NA |
3 |
800 |
32 |
NA |
88/7,420 |
Voxel Based Whole Brain |
SPM2 |
○ |
× |
× |
× |
× |
p<0.05 |
○ |
× |
× |
× |
FA↓ in SLF, CC, Cg, in ASD |
Sahyoun and colleagues [55] |
12 |
9 |
12.8 |
101 |
12 |
9 |
13.3 |
106 |
DSM-IV/ADI-R |
No/NA |
3 |
700 |
60 |
NA |
84/7,980 |
TBSS |
FSL |
○ |
○ |
× |
× |
× |
p<0.05 |
NA |
NA |
× |
○ |
FA↑ in bl UF, rt SLF, FA↓ in bl, SLF, bl FOF in ASD |
Thakkar and colleagues [56] |
12 |
10 |
30 |
116 |
14 |
8 |
27 |
114 |
DSM-IV/ADI-R/ADOS |
Yes/No |
3 |
700 |
60 |
NA |
82/8,400 |
Voxel Based Whole Brain |
FSL |
○ |
× |
× |
× |
× |
p<0.05 |
NA |
NA |
× |
× |
FA↓ in Cg in ASO |
Weinstein and colleagues [27] | 21 | NA | 3.3 | NA | 26 | NA | 3.3 | NA | DSM-IV/ADI-R/ADOS | NA/No | 1.5 | 1,000 | 15 | 2 | 94/1,1000 | TBSS | FSL 0 | ○ | ○ | ○ | ○ | × | p<0.05 | NA | NA | ○ | × | FA↑ in lt SLF, bl Cg, CC in ASD |
aNumber of ASD participants. bMean IQ of participants. cNumber of controls. AD axial diffusivity, ADC apparent diffusion coefficient, ADIR Autism Diagnostic Interview-Revised, ADOS Autism Diagnostic Observation Schedule, ASD autism spectrum, AF arcuate fasciculus, bl bilateral, CC corpus callosum, Cg cingulum, DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV, FA fractional anisotropy, FDR false discovery rate, FSL FMRIB Software Library, FWE family wise error, ICD-10 International Statistical Classification of Diseases and Related Health Problems-10, IFOF inferior frontal occipital fasciculus, ILF inferior frontal occipital fasciculus, lt left, MD mean diffusivity, NA not available, NEX number of excitation, RD radial diffusivity, rt right, SLF superior longitudinal fasciculus, SPM statistical parametric mapping, TBSS tract-based spatial statistics, TD typically developing, TE echo time, TFCE threshold, free cluster enhancement, TR repetition time, UF uncinate fasciculus, WBA whole brain analysis.